M&G Investment Management Ltd. Has $12.12 Million Stock Holdings in Organon & Co. (NYSE:OGN)

M&G Investment Management Ltd. lifted its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 279.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 866,003 shares of the company's stock after acquiring an additional 638,016 shares during the period. M&G Investment Management Ltd. owned 0.34% of Organon & Co. worth $12,124,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Lindbrook Capital LLC lifted its stake in shares of Organon & Co. by 348.3% during the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company's stock worth $27,000 after purchasing an additional 1,428 shares during the period. Harvest Fund Management Co. Ltd boosted its stake in Organon & Co. by 495.5% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company's stock worth $28,000 after buying an additional 1,333 shares during the last quarter. Gladius Capital Management LP grew its holdings in Organon & Co. by 65.1% in the 4th quarter. Gladius Capital Management LP now owns 2,176 shares of the company's stock valued at $31,000 after buying an additional 858 shares during the period. Headlands Technologies LLC acquired a new position in shares of Organon & Co. during the 3rd quarter valued at about $35,000. Finally, GAMMA Investing LLC purchased a new position in shares of Organon & Co. during the 4th quarter worth about $38,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Trading Up 2.0 %

Shares of Organon & Co. stock traded up $0.41 during trading hours on Tuesday, hitting $21.35. The company's stock had a trading volume of 2,142,031 shares, compared to its average volume of 2,683,795. The business has a fifty day moving average of $18.61 and a 200 day moving average of $16.01. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.08. The company has a quick ratio of 1.15, a current ratio of 1.65 and a debt-to-equity ratio of 181.35. The company has a market capitalization of $5.49 billion, a PE ratio of 5.22, a P/E/G ratio of 0.86 and a beta of 0.81.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. Organon & Co. had a net margin of 16.50% and a negative return on equity of 360.57%. The firm had revenue of $1.60 billion during the quarter, compared to analysts' expectations of $1.55 billion. As a group, equities analysts forecast that Organon & Co. will post 4.36 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 annualized dividend and a dividend yield of 5.25%. Organon & Co.'s payout ratio is currently 27.38%.

Insider Buying and Selling

In other news, insider Kirke Weaver bought 2,720 shares of the firm's stock in a transaction dated Thursday, February 22nd. The stock was acquired at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the purchase, the insider now owns 15,181 shares of the company's stock, valued at $278,723.16. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 1.17% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on OGN shares. Piper Sandler upped their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Monday, April 29th. The Goldman Sachs Group increased their target price on Organon & Co. from $18.00 to $20.00 and gave the stock a "neutral" rating in a research report on Friday, May 3rd.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.